VX-135

DRUG3 trials

Sponsors

Vertex Pharmaceuticals Incorporated, Alios Biopharma Inc.

Conditions

CHCChronic Hepatitis CHCVHepatitis C

Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

CompletedNCT01726946

Vertex Pharmaceuticals IncorporatedChronic Hepatitis C

Start: 2012-11-30End: 2014-02-28Updated: 2015-04-16

A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

CompletedNCT01790100

Alios Biopharma Inc.Chronic Hepatitis C

Start: 2013-02-28End: 2014-06-30Updated: 2017-12-18

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

CompletedNCT01842451

Vertex Pharmaceuticals IncorporatedCHC, Chronic Hepatitis C, HCV +1

Start: 2013-06-30End: 2014-05-31Updated: 2015-12-29